LBA-1 The Phase III Study: Targeted intra-arterial gemcitabine vs. continuation of IV gemcitabine plus nab-paclitaxel following induction with sequential IV gemcitabine plus nab-paclitaxel and radiotherapy for locally advanced pancreatic cancer (TIGeR-PaC)
Year: 2023
Type: article
Study design: Clinical Trial
Source: Annals of Oncology
Institutions: Johns Hopkins University, Yale University, Oregon Health & Science University, Portland VA Medical Center, East Carolina University, University of Oklahoma Health Sciences Center, University of Iowa, University of Miami, West Virginia University, Medical University of South Carolina, UPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Sarasota Memorial Hospital, Sarasota Memorial Health Care System, Moffitt Cancer Center, Atrium Health Wake Forest Baptist, Sutter Health, Sutter Medical Center, New York State Psychiatric Institute, Columbia University, RenovoRx, Inc. (United States), Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4382806733